Clinical Trial: Camrelizumab Combined with Apatinib and Hepatic Artery Infusion Chemotherapy (HAIC) As Conversion Therapy for Unresectable Hepatocellular Carcinoma(HCC)

U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06796803) titled 'Camrelizumab Combined with Apatinib and Hepatic Artery Infusion Chemotherapy (HAIC) As Conversion Therapy for Unresectable Hepatocellular Carcinoma(HCC)' on Jan. 22.

Brief Summary: The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with apatinib and HAIC as conversion therapy for unresectable HCC.

Study Start Date: Feb. 20

Study Type: INTERVENTIONAL

Condition: Potentially Resectable Hepatocellular Carcinoma

Intervention: DRUG: camrelizumab combined with apatinib and HAIC

systemic therapy combined with locoregional theraphy as conversion therapy

DRUG: camerlizumab+apatinib ...